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Synopsis (=< 100 words) 
VERDICT (Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumours) MRI is a 
diffusion imaging technique which has shown promise in revealing information about tumour 
microstructure beyond ADC measures and structural imaging. We report the first application of 
VERDICT to human brain tumours. In this feasibility study, we characterise a mixed group of brain 
tumours using VERDICT, which includes a range of both low and high-grade gliomas; compare the 
VERDICT parameter maps with ADC maps, post-contrast T1w images and histological grading; and 
examine the repeatability of the technique. 
 
Introduction:  Gliomas are the most common primary malignant adult brain tumours. Glioblastoma 
(GBM) is the most aggressive subtype with a 5-year survival of less than 10%.  For therapeutic trials in 
gliomas, traditional imaging predominantly focuses on the contrast-enhancing component of the 
tumour with only qualitative assessment of non-enhancing tumour1. With several therapeutic options 
now available for relapsed/recurrent disease, including vaccines and immunotherapy, better imaging 
assessment of tumour burden is needed.  Vascular, Extracellular, and Restricted Diffusion for 
Cytometry in Tumours (VERDICT) is a diffusion MRI technique which is combined with mathematical 
modelling to non-invasively estimate and map microstructural tissue parameters such as cell density, 
radius and vascular perfusion2. Previously, VERDICT has been shown to differentiate malignant 
prostate cancer from benign pathology3. For the first time, we use VERDICT MRI to characterise both 
low and high-grade tumours. We apply a single three-compartment model to characterise a range of 
gliomas, compare with histological grading and examine the repeatability of the technique. 
 
Methods 
Study design: 9 untreated patients with brain tumours (3 glioblastoma (grade IV), 1 metastatic 
carcinoma (images not shown), 3 astrocytoma (II/III), 2 oligodendroglioma (II)) were scanned at 3T 
(Achieva, Philips) using an 8-channel head coil. Nine diffusion weightings were acquired (3-
orthogonal directions, b = 80-3000 s/mm2) with a single-shot SE-EPI readout with the following 
parameters: TR = 3.7s, TE = min, FA = 90°, DM = 922, voxel size = 2.5mm3, slices = 33, averages = 1. A 
15-direction DTI scan was also acquired (b = 700 s/mm2). Acquisition time was 12 minutes. DWIs 
were normalised to B0 (b = 0) images acquired with the same TE. Five patients immediately 
underwent a second set of same-session scans for assessment of repeatability. For quantitative 
assessment, the repeatability coefficient was calculated for each parameter4. 
Image processing and analysis: Diffusion images were registered and corrected for eddy current 
effects using the ECMOCO toolbox in SPM5. For VERDICT analysis, tumour masks were created by 
manual segmentation of B0 images. Voxel-wise fitting with VERDICT was conducted across the ROIs. 
A BallSphereStick model was used to estimate microstructural parameters including intracellular 
volume fraction (fic), extracellular v.f. (fees), vascular v.f (fv) and cell radius index. The diffusivities of 
each compartment were fixed for stability (dic = 1x10-9, dees = 2x10-9, dv = 8x10-9 m2/s). ADC maps 
were also generated for each patient. Mean parameter values were calculated for each parameter 
by averaging across the tumour ROI. Note, in the GBMs, the peri-tumour zone was fitted but 
excluded from mean parameter calculations so that only bulk tumour regions were compared. 
 
Results 
ADC values were elevated in tumour regions compared to normal brain for all gliomas types, as 
expected6 (Fig 1). ADC was highest in GBMs (Fig 2a). The astrocytoma and oligodendroglioma had 
comparable mean ADC values, whilst the metastatic carcinoma demonstrated the lowest ADC. 
VERDICT parameter maps in the GBMs (Fig 2d-f) showed a rim around the core of the tumour where 
the fic, radius and cellularity (= fic/radius3) parameters were raised compared to the centre, 
consistent with a region of higher cell density surrounding a necrotic core. Interestingly, the 
parameter maps were non-uniform across the peri-tumour zone indicating variations in the 
underlying microstructure within this region. In the astrocytoma radius parameter and cellularity 
index maps (Fig 1j-l), there were areas of increased cellularity and reduced radius not seen as clearly 
in the corresponding structural image (Fig 1g) and ADC map (Fig 1i), which have a more uniform 
appearance. In the oligodendroglioma radius parameter map (Fig 1q), many voxels hit the upper 
fitting bound (of 20µm) suggesting that the modelling needs further adaptation for this tumour 
subtype. 
Overall, the cellularity index was elevated in the grade IV GBMs (Fig 2f) compared to the grade II/III 
astrocytomas and oligodendrogliomas. The highest cellularity value was in the metastatic carcinoma. 
The VERDICT radius parameter was reduced in the GBMs compared to the astrocytomas and 
oligodendrogliomas (Fig 2e), however, this may be related to the fitting in the lower grade subtypes. 
Repeatability was generally excellent for all VERDICT parameters (Fig 3) with a repeatability 
coefficient <7% except for the cellularity parameter (15.5%). 
 
Discussion 
We have demonstrated that VERDICT is feasible in human gliomas and potentially provides 
information that corresponds to histological grading, which goes beyond ADC and conventional 
imaging. We are currently working on further validation of the VERDICT parameters with detailed 
histological analysis. Future work will focus on optimisation of the diffusion scans to permit shorter 
acquisition times for a clinically viable sequence that could potentially have important implications 
for pre-surgical planning and assessment of therapeutic response. 
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Figure 1: Structural images, ADC maps and VERDICT parameter maps from patients with three different types of glioma: 
(a-f) grade IV glioblastoma, (g-l) grade II astrocytoma and (m-r) grade II oligodendroglioma (fic = intracellular volume 
fraction, radius = cell radius index, cellularity). 
 
 Figure 2: (a) ADC and (b-f) VERDICT parameters (fic = intracellular volume fraction, fees = extracellular-extravascular 
volume fraction, fv = vascular volume fraction, radius = cell radius index, cellularity) from four types of brain tumour 
(GBM = glioblastoma, Met = metastatic carcinoma, Astro = astrocytoma, Oligo = oligodendroglioma). 
 
 
 
Figure 3: Repeatability of VERDICT parameters in five patients and corresponding repeatability coefficients (fic = 
intracellular volume fraction, fees = extracellular-extravascular volume fraction, fv = vascular volume fraction, radius = 
cell radius index, cellularity). 
